Development and characterization of novel erythropoiesis stimulating protein (NESP)

J C Egrie, J K Browne, J C Egrie, J K Browne

Abstract

Studies on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of the molecule and its serum half-life and in vivo biological activity, but an inverse relationship with its receptor-binding affinity. These observations led to the hypothesis that increasing the carbohydrate content, beyond that found naturally, would lead to a molecule with enhanced biological activity. Hyperglycosylated recombinant human EPO (rHuEPO) analogues were developed to test this hypothesis. Darbepoetin alfa (novel erythropoiesis stimulating protein, NESP, ARANESP, Amgen Inc, Thousand Oaks, CA), which was engineered to contain 5 N-linked carbohydrate chains (two more than rHuEPO), has been evaluated in preclinical animal studies. Due to its increased sialic acid-containing carbohydrate content, NESP is biochemically distinct from rHuEPO, having an increased molecular weight and greater negative charge. Compared with rHuEPO, it has an approximate 3-fold longer serum half-life, greater in vivo potency, and can be administered less frequently to obtain the same biological response. NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence.

Copyright 2001 Cancer Research Campaign.

References

    1. J Am Soc Nephrol. 1999 Nov;10(11):2392-5
    1. J Biol Chem. 1992 Apr 15;267(11):7703-9
    1. J Biol Chem. 1974 Jul 10;249(13):4202-6
    1. J Biol Chem. 1977 Aug 10;252(15):5558-64
    1. Proc Natl Acad Sci U S A. 1984 Mar;81(6):1779-83
    1. Endocrinology. 1985 Jun;116(6):2293-9
    1. J Biol Chem. 1986 Mar 5;261(7):3116-21
    1. Glycobiology. 1991 Mar;1(2):115-30
    1. Biochemistry. 1992 Oct 20;31(41):9871-6
    1. Drugs. 1995 Feb;49(2):232-54
    1. Cold Spring Harb Symp Quant Biol. 1995;60:93-104
    1. Blood. 1997 Jun 15;89(12):4248-67
    1. Nature. 1998 Oct 1;395(6701):511-6
    1. Nat Struct Biol. 1998 Oct;5(10):861-6
    1. Haematologica. 1998 Aug;83(8):724-32
    1. Int J Mol Med. 1998 Feb;1(2):303-14
    1. Nature. 1960 Jan 9;185:102-3
    1. J Biol Chem. 1987 Sep 5;262(25):12059-76
    1. Lancet. 1986 Nov 22;2(8517):1175-8
    1. N Engl J Med. 1987 Jan 8;316(2):73-8
    1. Immunobiology. 1986 Sep;172(3-5):213-24
    1. Cold Spring Harb Symp Quant Biol. 1986;51 Pt 1:693-702
    1. Biochemistry. 1987 May 5;26(9):2633-8
    1. J Biol Chem. 1987 Dec 15;262(35):17156-63
    1. J Biol Chem. 1988 Mar 15;263(8):3657-63
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6513-7
    1. Biochemistry. 1988 Jul 26;27(15):5646-54
    1. J Biol Chem. 1988 Nov 25;263(33):17516-21
    1. Blood. 1989 Jan;73(1):84-9
    1. Blood. 1989 Jan;73(1):90-9
    1. Biochemistry. 1988 Nov 15;27(23):8618-26
    1. Cell. 1989 Apr 21;57(2):277-85
    1. Ann Intern Med. 1989 Dec 15;111(12):992-1000
    1. JAMA. 1990 Feb 9;263(6):825-30
    1. Blood. 1991 Feb 1;77(3):419-34
    1. J Biol Chem. 1991 Dec 5;266(34):23022-6
    1. Can J Biochem. 1972 Aug;50(8):909-17

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi